


Approved prescription drug products with therapeutic equivalence evaluations.

[Washington, D.C.?] : U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Bureau of Drugs : 1980-

<http://hdl.handle.net/2027/mdp.39015072933024>

HathiTrust



www.hathitrust.org

Public Domain, Google-digitized

http://www.hathitrust.org/access_use#pd-google

We have determined this work to be in the public domain, meaning that it is not subject to copyright. Users are free to copy, use, and redistribute the work in part or in whole. It is possible that current copyright holders, heirs or the estate of the authors of individual portions of the work, such as illustrations or photographs, assert copyrights over these portions. Depending on the nature of subsequent use that is made, additional rights may need to be obtained independently of anything we can address. The digital images and OCR of this work were produced by Google, Inc. (indicated by a watermark on each page in the PageTurner). Google requests that the images and OCR not be re-hosted, redistributed or used commercially. The images are provided for educational, scholarly, non-commercial purposes.

HE 20.4210:983 / SUPP. 6

999-11-3

The University
of Michigan
Pharmacy
Library

SERIAL


REFERENCE

REFERENCE
DOES NOT CIRCULATE

CUMULATIVE
SUPPLEMENT 6
AUG'83 - FEB'84

Pharm.
RM
300
19653

4th ed.
Suppl. 6



APPROVED
PRESCRIPTION
DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

4TH EDITION

UNIVERSITY OF MICHIGAN
LIBRARIES

MAY 8 1984

DEPOSITED BY THE
UNITED STATES OF AMERICA

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
NATIONAL CENTER FOR DRUGS AND BIOLOGICS



FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 4th Edition (the List), to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature, are identified by the term "list". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the DESI Addendum.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1983. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLI> (DELETE) to the left of the line containing the overstruck print. The >DLI> symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (☒) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month.

Because we are converting to a new automated data processing system, cumulative counts shown for the quarter ending January 1984, represent approximate values. Accurate quarterly values will be shown in the Cumulative Supplement 7. Monthly values shown in Supplement 6 for February 1984, are accurate.

B. PRODUCTS CONTAINING PHENACETIN

The October 5, 1983, Federal Register (48FR45466) provides the following Summary: "The Food and Drug Administration (FDA) is withdrawing approval of new drug applications or parts of new drug applications that provide for drug products containing phenacetin, except for those drug products that are the subject of a hearing request. The basis of the withdrawal is phenacetin's high potential for misuse and its unfavorable benefit-to-risk ratio when incorporated in analgesic combinations which are then subject to excessive chronic use." The effective date of this withdrawal order is November 4, 1983.

Because the subject products are no longer approved, the cumulative supplement has identified them by deleting the applicable active ingredient headers followed by a reference to this Special Note.

C. THEOPHYLLINE CONTROLLED RELEASE

Two controlled released theophylline tablets are listed as therapeutically equivalent (AB). Because one of these products was recently approved for once-daily dosing, it is important to be aware that the therapeutic equivalence rating was made on the basis of 12-hour dosing intervals. The rating does not apply to once-daily dosing. To date, no data have been submitted upon which the Agency can base a therapeutic equivalence determination among any of the approved theophylline controlled-release products when dosed once-daily.

D. APPLICANT (NAME) CHANGES

Because it is not practical to identify in the cumulative supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this Special Notes section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the cumulative supplement. The current list of applicant holder changes follows.

APPLICANT (NAME) CHANGES

<u>Former Applicant (Name)</u>	<u>New Applicant (Name)</u>	<u>New Abbreviated Name</u>
STERI-MED INC SUB KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
PROFESSIONAL PHARMACAL DIV STERI-MED INC	OPTOPICS LABORATORIES CORP	OPTOPICS LABS

The reader should consult the above cumulative list each month to become aware of such transfers and changes. By referring to the Applicant Index in the 4th Edition of the APDP, the transferred products can be identified. The reader might wish to flag these products in the List as a reminder that the applicant has been changed.

This report provides counts in several categories from the List composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excited also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristic is package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

Drug Product Count

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

New Molecular Entity

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

Drug Product Definition

From the data presented under Section B., users should be able to observe such things as (1) newly approved, DESI effective and marketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval; changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either multistore or single source during each month within the quarter. The report does not reflect category changes from multistore to single source and vice versa. However, the net gain that results from all additions, deletions and category changes is reflected in the quarterly counts for multi-store and single source products.

USE OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July 1, 83. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

DESCRIPTION OF REPORT

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

CATEGORIES COUNTED	JULY '83 (BASELINE)	OCT '83	JAN '84 (SEE SPECIAL NOTE A.)
DRUG PRODUCTS LISTED	6679	6783	6854
SINGLE SOURCE	1908 (28.6)	1915 (28.2%)	1925 (28.1%)
MULTISOURCE ⁽¹⁾	4771 (71.4)	4868 (71.8%)	4929 (71.9%)
THERAPEUTICALLY EQUIVALENT	3804 (57.0%)	3891 (57.4%)	3947 (57.6%)
NOT THERAPEUTICALLY EQUIVALENT	957 (14.3%)	967 (14.3%)	972 (14.2%)
EXCEPTIONS ⁽²⁾	10 (0.1%)	10 (0.1%)	10 (0.1%)
NEW MOLECULAR ENTITIES APPROVED	-	2	8
NUMBER OF APPLICANTS	304	310	309

B. ACTIVITY FOR SUPPLEMENT NUMBER 6

	FEB '84	CUMULATIVE
DRUG PRODUCTS ADDED:		
NEWLY APPROVED	28	28
DESI EFFECTIVE	0	0
REMARKETED	0	0
DRUG PRODUCTS REMOVED:	7	7
WITHDRAWN APPROVAL	0	0
RX TO OTC SWITCH	0	0
DISCONTINUED MARKETING	9	9
NET GAIN IN DRUG PRODUCTS	21	21
SINGLE SOURCE PRODUCTS APPROVED	4	4
MULTISOURCE DRUG PRODUCTS APPROVED	24	24
NEW MOLECULAR ENTITIES APPROVED:	0	0
AS THE ENTITY	0	0
AS A SALT, ESTER OR DERIVATIVE OF THE ENTITY	0	0

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (I.e., AVAILABLE FROM MORE THAN ONE APPLICANT)

(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 1-5 OF THE LIST)

APPROVED PRESCRIPTION DRUG PRODUCTS
DRUG PRODUCT LIST
CUMULATIVE SUPPLEMENT NUMBER 6 / AUGUST '83 - FEBRUARY '84

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

CAPSULE; ORAL <u>ACETAMINOPHEN W/ CODEINE #3</u>			
AA	LEMON	300MG;30MGx	
<u>TYLENOL W/ CODEINE NO. 3</u>			
AA	MCNEIL PHARM	300MG;30MG	
TABLET; ORAL <u>ACETAMINOPHEN AND CODEINE PHOSPHATE</u>			
> ADD > AA	DURAMED PHARMS	300MG;15MGx	
> ADD > AA		300MG;30MGx	
> ADD > AA		300MG;60MGx	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE (PAGE 3-2)

TABLET; ORAL <u>CODACET</u>			
AA	HALSEY DRUG	325MG;5MGx	
<u>/PERCOCET-5/ PERCOSET</u>			

/ACETAMINOPHEN; PHENACETIN; PHENYLPROPANOLAMINE HYDROCHLORIDE/;
/PHENYLTOLOXAMINE CITRATE/ (PAGE 3-2)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ALBUMIN, IODINATED, I-131, SERUM (PAGE 3-4)

INJECTABLE; INJECTION
/RADIOIODINATED SERUM ALBUMIN (HUMAN) I-131/
/MALLINCKRODT/ 16.7-250.0U/ML/

AMINO ACIDS (PAGE 3-6)

INJECTABLE; INJECTION
NEOPHAM 6.5%
CUTTER-VITRUM 6.5%x

AMINOPHYLLINE (PAGE 3-8)

<u>/LIQUID; ORAL/ SOLUTION; ORAL AMINOPHYLLINE</u>			
AA	BAY LABORATORIES	105MG/5MLx	
AA	ROXANE LABORATORIES	105MG/5MLx	

AMINOPHYLLINE (PAGE 3-8)

TABLET; ORAL <u>AMINOPHYLLINE</u>			
BD	BARR LABORATORIES	100MGx	
BD		200MGx	
AB	VANGARD LABS/MNM	100MGx	
AB		200MGx	

/AMPHETAMINE SULFATE/ (PAGE 3-13)

<u>/CAPSULE; CONTROLLED RELEASE; ORAL /BENZEDRINE/ /SK&F. LABORATORIES/ 15MG/</u>			
<u>/TABLET; ORAL/ /BENZEDRINE/ /SK&F. LABORATORIES/ 5MG/ 10MG/</u>			

AMPICILLIN TRIHYDRATE; PROBENECID (PAGE 3-13)

POWDER FOR RECONSTITUTION; ORAL <u>POLYCILLIN-PRB</u>			
AB	BRISTOL LABS/B-M	EQ 3.5GM BASE/BOT;1GM/BOT	
AB	PROBAMPACIN		
AB	BIOCRAFT LABS	EQ 3.5GM BASE/BOT;1GM/BOT	

ASPIRIN; BUTALBITAL (PAGE 3-15)

TABLET; ORAL AXOTAL			
	ADRIA LABORATORIES	650MG;50MGx	

ASPIRIN; BUTALBITAL; CAFFEINE (PAGE 3-15)

TABLET; ORAL <u>ASPIRIN AND CAFFEINE W/ BUTALBITAL</u>			
AB	PUREPAC/KALIPHARMA	325MG;50MG;40MGx	
AB	BUTALBITAL W/ ASPIRIN & CAFFEINE		
AB	BOOTS LABORATORIES	325MG;50MG;40MGx	

/ASPIRINS BUTALBITALS CAFFEINE; PHENACETIN/ (PAGE 3-15)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

BETAMETHASONE VALERATE (PAGE 3-21)

CREAM; TOPICAL

BETATREXAB SAVAGE LABS/BYK-GLDN EQ 0.1% BASEN

LOTION; TOPICAL

BETAMETHASONE VALERATEAB E FOUGERA/BYK-GLDN EQ 0.1% BASENAB PHARMADERM/BYK-GLDN EQ 0.1% BASENBETATREXAB SAVAGE LABS/BYK-GLDN EQ 0.1% BASENVALISONEAB SCHERING EQ 0.1% BASE

OINTMENT; TOPICAL

BETAMETHASONE VALERATEAB E FOUGERA/BYK-GLDN EQ 0.1% BASENAB PHARMADERM/BYK-GLDN EQ 0.1% BASENBETATREXAB SAVAGE LABS/BYK-GLDN EQ 0.1% BASENVALISONEAB SCHERING EQ 0.1% BASE> ADD > BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE (PAGE 3-22)

> ADD > SYRUP; ORAL

> ADD > AMBENYL

> ADD > MARION LABORATORIES 12.5MG/5ML;10MG/5ML

BROMPHENIRAMINE MALEATE (PAGE 3-22)

TABLET; ORAL

BROMPHENIRAMINE MALEATE/AA/ /BOLAR PHARMACEUTICAL/ 6MG/BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE (PAGE 3-23)

INJECTABLE; INJECTION

MARCaine HCl w/ EPINEPHRINEAP BREON LABS/STERLING 0.5%:0.0091MG/MLAP 0.75%:0.0091MG/MLSENSORGAINAP ASTRA HOSP PHARM 0.5%:0.0091MG/MLAP 0.75%:0.0091MG/MLBUTABARBITAL SODIUM (PAGE 3-24)

CAPSULE; ORAL

BUTICAPS

/MCNEIL LABORATORIES// 15MG/

30MG/

50MG/

100MG/

WALLACE LABS/C-W

15MG

30MG

50MG

100MG

ELIXIR; ORAL

/BUTABARBITAL SODIUM//AA/ /WESTWARD/ 15MG/5ML/

BUTALAN

/AA/ LANNETT 33.3MG/5ML/CAFFEINE; CARISOPRODOL; CODEINE PHOSPHATE; PHENACETIN/ (PAGE 3-24)

/TABLET; ORAL/

/SOMA COMPOUND N/; CODEINE/

/WALLACE PHARMS/C-W/ 32MG;200MG;16MG;160MG/

/CAFFEINE; CARISOPRODOL; PHENACETIN/ (PAGE 3-25)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

CAFFEINE; ERGOTAMINE TARTRATE (PAGE 3-25)

SUPPOSITORY; RECTAL

CAFERGOT

BR SANDOZ PHARMS/SANDOZ 100MG;2MG

MIGRAINE

BR ORGANON/AKZONA 100MG;2MG

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE (PAGE 3-26)

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE w/ DEXTROSE 30% IN PLASTIC CONTAINER

AM MCGAW/AM HOSP 510MG/100ML;30GM/100ML;

200MG/100ML;9.2GM/100ML;

9.6GM/100ML

510MG/100ML;30GM/100ML;

200MG/100ML;9.4GM/100ML;

11GM/100ML

CHLOROTHIAZIDE (PAGE 3-35)

TABLET; ORAL

CHLOROTHIAZIDE

AB CHELSEA LABORATORIES 250MG^x
 AB 500MG^x

CHLOROTHIAZIDE; RESERPINE (PAGE 3-35)

TABLET; ORAL

CHLOROTHIAZIDE AND RESERPINE

BP WEST-WARD 250MG; 0.125MG^x
 BP 500MG; 0.125MG^x

CHLORPHENIRAMINE MALEATE (PAGE 3-36)

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

/AA/ /TOLNE PAULSEN/ 16MG/

CHLORPROPAMIDE (PAGE 3-38)

TABLET; ORAL

CHLORPROPAMIDE

> ADD > AB PAR PHARMACEUTICAL 100MG^x
 > ADD > AB 250MG^x
 > ADD > AB DIABINESE
 > ADD > AB PFIZER LABS/PFIZER 100MG

CHLORTHALIDONE (PAGE 3-38)

TABLET; ORAL

CHLORTHALIDONE

AB PUREPAC/KALIPHARMA 50MG^x

CHLORZOXAZONE (PAGE 3-39)

TABLET; ORAL

CHLORZOXAZONE

AA PAR PHARMACEUTICAL 250MG^x

CHYMOPAPAIN (PAGE 3-39)

INJECTABLE; INJECTION

DISCASETRAIVENOL LABS 12,500 UNITS/VIAL^xCIMETIDINE (PAGE 3-39)

TABLET; ORAL

TAGAMETSK&F LAB 400MG^xCLOTRIMAZOLE (PAGE 3-41)

> ADD > LOTION; TOPICAL
 > ADD > LOTRIMIN
 > ADD > SCHERING 1%^x

CORTICOTROPIN (PAGE 3-43)

INJECTABLE; INJECTION
 /REPOSITORY CORTICOTROPIN/
 /BC/ /HYETH LABS/AMHO/ 40 UNITS/ML/
 /BC/ / / 50 UNITS/ML/

CYANOCOBALAMIN (PAGE 3-44)

INJECTABLE; INJECTION
 CYANOCOBALAMIN
 > ADD > AP SOLOPAK/MPL 1MG/ML^x
 AP DODECAMIN
 MAURRY BIOLOGICAL 1MG/ML^x
 /AB/ REDISOL
 MS&D/MERCK 0.1MG/ML^x
 /AB/ SYTOBEX
 PARKE DAVIS/W-L 0.1MG/ML^x

CYCLOSPORINE (PAGE 3-46)

INJECTABLE; INJECTION
 SANDIMMUNE
 SANDOZ PHARMS/SANDOZ 50MG/ML^x

SOLUTION; ORAL
 SANDIMMUNE
 SANDOZ PHARMS/SANDOZ 100MG/ML^x

CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-46)

TABLET; ORAL
 CYPROHEPTADINE HCL
 > ADD > AA DURAMED PHARMS 6MG^x
 PIONEER PHARMS 6MG^x

DAPSONE (PAGE 3-47)	TABLET; ORAL /B/H /AYERS, LABS/AND/ /500mg/	DEXTROSE; DOPAMINE HYDROCHLORIDE (PAGE 3-53)	INJECTABLE; INJECTION /DOPAMINE, HCl, IN DEXTROSE, 5%/ DEXTROSE; DOPAMINE HCl ABOTT LABORATORIES 500/1000; 800/1000; DOPAMINE HCl IN PLASTIC CONTAINER DEXTROSE; HEPARIN SODIUM 500/1000; 1600/2000; HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER TRAVENOL LABS 500/1000; 4,000 UNITS/100ML SOLUTION; ORAL DEXAMETHASONE 0.5MG/MLX DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM (PAGE 3-57)	0.25%	TOPICORT HOCHEST-ROUSSEL	DESOXIMETASONE (PAGE 3-49)	SOLUTION; ORAL DEXAMETHASONE 0.5MG/MLX DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM (PAGE 3-57)	ROXANE LABORATORIES 0.5MG/0.5MLX DEXAMETHASONE INTENSOL ROXANE LABORATORIES 0.5MG/5MLX DIATRIZOATE-60 TABELET; ORAL MSD/MERCK 6MG DECADRON DEXAMETHASONE 6MG DIETHYLPROPION HYDROCHLORIDE (PAGE 3-59)	INJECTABLE; INJECTION /DIMEHYDRINATE /66/ /INT'L MEDICAL/INT'L Sys//500mg/ML/ DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)	AP	INJECTABLE; INJECTION /DIMEHYDRINATE /66/ /INT'L MEDICAL/INT'L Sys//500mg/ML/ DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)	AP	INJECTABLE; INJECTION /DIMEHYDRINATE /66/ /INT'L MEDICAL/INT'L Sys//500mg/ML/ DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)	AP	INJECTABLE; INJECTION /DIMEHYDRINATE /66/ /INT'L MEDICAL/INT'L Sys//500mg/ML/ DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)	AP	INJECTABLE; INJECTION /DIMEHYDRINATE /66/ /INT'L MEDICAL/INT'L Sys//500mg/ML/ DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)	AP	EXDARDOL /EXDARDOL PHOSPHATE/ > ADD > AP ORGANON/AKZONA EG 4MG PHOSPHATE/ML HEXDAROL /HEXDAROL PHOSPHATE/ > ADD > AP DEexamethasone sodium sys EG 20MG PHOSPHATE/ML INTRAL MEDICATION SY EG 20MG PHOSPHATE/ML > ADD > AP DEexamethasone sodium phosphate/ML INTRAL MEDICATION SY EG 10MG PHOSPHATE/ML INTRAL MEDICATION SY EG 4MG PHOSPHATE/ML DEexamethasone sodium phosphate/ML INJECTABLE; INJECTION /DIMEHYDRINATE /66/ /INT'L MEDICAL/INT'L Sys//500mg/ML/ DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)	CAPSULE; ORAL SK&F LABORATORIES /250mg/ ELIXIR; ORAL BELIX AA HALSEY DRUG DEBENTL AA HR CENCI LABS 12.5MG/5MLx 12.5MG/5MLx SOLUTION/DROPS; OPHTHALMIC DEXTAR PHARMACEUTICAL EG 0.12 PHOSPHATE DEXAMETHASONE SODIUM PHOSPHATE EG 0.12 PHOSPHATE BARNEs-HIND PHARMS EG 0.12 PHOSPHATE AI
---------------------	--	--	---	-------	-----------------------------	----------------------------	--	---	--	----	--	----	--	----	--	----	--	----	--	--

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)

ELIXIR; ORAL

DIPHENHYDRAMINE HCL

>DLT >AA /CORD LABORATORIES/ /12.5MG/5ML/
 /SK DIPHENHYDRAMINE/
 /AA/ /SK&F. LABORATORIES/ /12.5MG/5ML/

DISULFIRAM (PAGE 3-63)

TABLET; ORAL

DISULFIRAM

BX CHELSEA LABORATORIES 250MG
 BX 500MG
 BX SIDMAK LABORATORIES 250MG
 BX 500MG

DOXYCYCLINE HYCLATE (PAGE 3-64)

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB CHELSEA LABORATORIES EQ 50MG BASE
 AB HEATHER DRUG EQ 50MG BASE
 AB EQ 100MG BASE
 AB PAR PHARMACEUTICAL EQ 100MG BASE
 AB PUREPAC/KALIPHARMA EQ 50MG BASE
 AB EQ 100MG BASE

INJECTABLE; INJECTION

DOXY 100

AP LYPHO-MED EQ 100MG BASE/VIAL
 AP DOXY 200 EQ 200MG BASE/VIAL
 AP LYPHO-MED EQ 200MG BASE/VIAL
 AP DOXYCYCLINE
 AP ELKINS-SINN EQ 100MG BASE/VIAL
 AP EQ 200MG BASE/VIAL
 AP VIBRAMYCIN
 AP PFIZER LABS/PFIZER EQ 200MG BASE/VIAL

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB HEATHER DRUG EQ 100MG BASE

DROPERIDOL; FENTANYL CITRATE (PAGE 3-64)

INJECTABLE; INJECTION

INNOVAR

/JANSSEN PHARMA/ /2.5MG/ML; 0.05MG/ML/
 JANSSEN PHARMA 2.5MG/ML; EQ 0.05MG BASE/ML

DYCLONINE HYDROCHLORIDE (PAGE 3-64)

SOLUTION; TOPICAL

DYCLONE

>DLT >
 >DLT >
 >ADD > MERRELL DOW/DOW CHEM/0.5%/
 >ADD > ASTRA PHARM PRODS 0.5%
 1%

ECHOTHIOPHATE IODIDE (PAGE 3-65)

POWDER FOR RECONSTITUTION; OPHTHALMIC

/ECHOTIOPHATE/
 /AT/ /ALCON LABORATORIES/ /0.05%/
 /AT/ /0.06%/
 /AT/ /0.125%/
 /AT/ /0.25%/
 /AT/ /AYERST LABS/AMHO 0.03%
 /AT/ 0.06%
 /AT/ 0.125%
 /AT/ 0.25%

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE (PAGE 3-66)

INJECTABLE; INJECTION

LIDOCATON

AP PHARMATON/SZ 0.01MG/ML; 22ML
 AP 0.02MG/ML; 22ML

ERGOLOOID MESYLATES (PAGE 3-66)

CAPSULE; ORAL
 /HYPERFINE/
 HYDERGINE LC

ERYTHROMYCIN (PAGE 3-67)

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT E FOUGERA/BYK-GLDN 5MG/GM
 AT PHARMADERM/BYK-GLDN 5MG/GM
 AT ZLOTYCIN
 AT DISTA PRODS/LILLY 5MG/GM

ESTRADIOL (PAGE 3-69)

>ADD > CREAM; VAGINAL
 >ADD > ESTRACE
 >ADD > MEAD JOHNSON/B-M 0.01%

GRISEOFULVIN, ULTRAMICROCRYSTALLINE (PAGE 3-82)

TABLET; ORAL
FULVICIN P/G 330
AB SCHERING **330MG**
GRISACTIN ULTRA
AB AYERST LABS/AMHO **165MGx**
AB **330MGx**

HEPARIN SODIUM (PAGE 3-83)

INJECTABLE; INJECTION
HEPARIN SODIUM
AP NATCON CHEMICAL **1,000 UNITS/MLx**

HEPARIN SODIUM; SODIUM CHLORIDE - IN PLASTIC (PAGE 3-85)

INJECTABLE; INJECTION
 HEPARIN SODIUM 5000 UNITS IN SODIUM CHLORIDE 0.45%
 ABBOTT LABORATORIES 100 UNITS/ML;4.5MG/MLx
 HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%
 ABBOTT LABORATORIES 10,000 UNITS/100ML;450MG/100MLx
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45%
 ABBOTT LABORATORIES 5,000 UNITS/100ML;450MG/100MLx
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%
 ABBOTT LABORATORIES 5,000 UNITS/100ML;450MG/100MLx
 10,000 UNITS/100ML;450MG/100MLx
 HEPARIN SODIUM 5000 UNITS IN SODIUM CHLORIDE 0.9%
 ABBOTT LABORATORIES 1,000 UNITS/100ML;900MG/100MLx
 HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%
 ABBOTT LABORATORIES 10,000 UNITS/100ML;900MG/100MLx
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%
 ABBOTT LABORATORIES 5,000 UNITS/100ML;900MG/100MLx
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%
 ABBOTT LABORATORIES 5,000 UNITS/100ML;900MG/100MLx

HOMATROPINE METHYLBROMIDE (PAGE 3-86)

TABLET; ORAL
HOMAPIN-10
/AA MISSION PHARMACAL **10MG**
/AA /SEUS-TENS 'SE/
/AA /JENMUN/ **/10MG/**

HYDRALAZINE HYDROCHLORIDE (PAGE 3-86)

TABLET; ORAL
HYDRALAZINE HCL
AA PAR PHARMACEUTICAL **100MGx**
AA PUREPAC/KALIPHARMA **50MGx**

HYDRALAZINE HYDROCHLORIDE; HYDROCHLORTIAZIDE; RESERPINE (PAGE 3-87)

TABLET; ORAL
/R-HClz-H/
 RESERPINE, HYDROCHLORTIAZIDE, AND HYDRALAZINE HCL
 RESERPINE, HYDRALAZINE HCL, AND HYDROCHLORTIAZIDE
BP REID-PROVIDENT LABS **25MG;15MG;0.1MGx**

HYDROCHLORTIAZIDE; RESERPINE (PAGE 3-89)

TABLET; ORAL
 RESERPINE AND HYDROCHLORTIAZIDE
BP CORD LABORATORIES **50MG;0.125MGx**

HYDROCHLORTIAZIDE; SPIRONOLACTONE (PAGE 3-89)

TABLET; ORAL
SPIRONOLACTONE w/ HYDROCHLORTIAZIDE
AB PUREPAC/KALIPHARMA **25MG;25MGx**

HYDROCORTISONE (PAGE 3-90)

CREAM; TOPICAL
ELDECORT
/AT/ ELDER PHARMS **/0.5%/**
HYDROCORTISONE
AT BAY LABORATORIES **1%
2.5%
5%**
 LOTION; TOPICAL
/ELACORT/
/AT/ MERICON INDUSTRIES/ **/0.5%/**
GLY-CORT
AT HERAN PHARMACEUTICAL **1%
2%
5%**
HYDROCORTISONE
AT MERICON INDUSTRIES **0.5%
1%
2%
5%**
/AT/ TOWNE PAULSEN/ **/0.5%/**

OINTMENT; TOPICAL
HYDROCORTISONE
AT BAY LABORATORIES **1%
2.5%
5%**
 /SOLUTION/DRPS; OPHTHALMIC/
/DTEF/
/UPJOHN/ **/0.2%/**

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 6 / AUGUST '83 - FEBRUARY '84

HYDROCORTISONE: NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-92)

SOLUTION/DROPS: OTIC
NEO-O-TOSOL-HG
CARTER-BLODGET LABS
HYDROCORTISONE ACETATE
CREAM: TOPICAL
/A/ /TOWNE, PAULSEN/ /12/
HYDROCORTISONE ACETATE
LOTION: TOPICAL
/A/
/Hydrocortisone Acetate/ 0.5%
Drichtor
/B/ /ANTIPHLESS/ /25MG/
/B/ /Lemon/ /IMRAT/ /25MG/
/A/ /AH, Roberts/ /25MG/
/A/ /PAR PHARMACEUTICAL/ 0.5%
WESTCORT
HYDROFLUMETHIAZIDE: RESERPINE (PAGE 3-95)
TABLET: ORAL
SOLUTION; INHALATION
ISOTETHIARINE HYDROCHLORIDE (PAGE 3-100)

QINTENON: TOPICAL
ISOTETHIARINE HYDROCHLORIDE (PAGE 3-100)
SOLUTION; INHALATION
ISOTETHIARINE HYDROCHLORIDE (PAGE 3-101)
BP COLMED LABORATORIES 50MG:0.125MGx
HYDROFLUMETHIAZIDE AND RESERPINE
TABLET: ORAL
SYRUP: ORAL
ISONIAZID
AA CAROLINA MED PRODS 50MG/5ML
AA RIMTON 50MG/5ML
AA HOFFMANN-LA ROCHE 50MG/5ML
DILODID-HP
INJECTABLE; INJECTION
HYDROMORPHONE HYDROCHLORIDE (PAGE 3-95)
BP COLMED LABORATORIES 50MG:0.125MGx
HYDROFLUMETHIAZIDE AND RESERPINE
TABLET: ORAL
ISONIAZID (PAGE 3-101)
BP COLMED LABORATORIES 50MG:0.125MGx
HYDROFLUMETHIAZIDE: RESERPINE (PAGE 3-95)
AM INT'L MEDICATION SVS 0.167Z
AM ROXANE LABORATORIES 0.167Z
AM TRAVENOL LABS 0.25Z
WESTWOOD PHARMS 0.2%
MESTCORT
HYDROFLUMETHIAZIDE; RESERPINE (PAGE 3-95)
TABLET: ORAL
ISONIAZID (PAGE 3-102)
BP COLMED LABORATORIES 50MG:0.125MGx
KNOOLL PHARMACEUTICAL 50MGx
HYDROXYZINE HYDROCHLORIDE (PAGE 3-96)
TABLET: ORAL
ISONIAZID
SOLUTION; INHALATION
>DLT >AN/ /INT'L MEDICATION SVS//6.5Z/

AB BARR LABORATORIES 25MGx
AB DANUERY PHARMACAL 25MGx
AB JOMEGA 50MGx
AB KNOOLL PHARMACEUTICAL 10MGx/MLx
HYDROXYZINE HC
TABLET: ORAL
ISONIAZID
SOLUTION; INHALATION
ISOPROTERENOL HYDROCHLORIDE (PAGE 3-102)

AB BARR LABORATORIES 25MGx
AB DANUERY PHARMACAL 25MGx
AB JOMEGA 50MGx
AB KNOOLL PHARMACEUTICAL 10MGx/MLx
HYDROXYZINE HYDROCHLORIDE (PAGE 3-96)
TABLET: ORAL
ISONIAZID
SOLUTION; INHALATION
ISOPROTERENOL HYDROCHLORIDE (PAGE 3-102)

KANAMYCIN SULFATE (PAGE 3-102)

INJECTABLE; INJECTION
KANAMYCIN SULFATE
AP INTL MEDICATION SYS EQ 500MG BASE/2MLX
AP EQ 1GM BASE/3MLX
KANTREX
/AP/ BRISTOL LABS/B-M /75MG/2ML/
/AP/ /500MG/2ML/
/AP/ /1GM/3ML/
AP BRISTOL LABS/B-M EQ 75MG BASE/2ML
AP EQ 500MG BASE/2ML
AP EQ 1GM BASE/3ML

LIDOCAINE HYDROCHLORIDE (PAGE 3-104)

INJECTABLE; INJECTION
LIDOCATON
AP PHARMATON/SZ 22%

METHOCARBAMOL (PAGE 3-117)

TABLET; ORAL
METHOCARBAMOL
> ADD > AA ROXANE LABORATORIES 500MGX
> ADD > AA 750MGX

METHYLPREDNISOLONE (PAGE 3-120)

TABLET; ORAL
METHYLPREDNISOLONE
> ADD > BP DURAMED PHARMS 4MGX

METHYLTESTOSTERONE (PAGE 3-121)

TABLET; BUCCAL/SUBLINGUAL
METHYLTESTOSTERONE
/BP/ /TOMME PAULSEN/ /10MG/

METRONIDAZOLE (PAGE 3-122)

INJECTABLE; INJECTION
METRONIDAZOLE
AP ABBOTT LABORATORIES 500MG/100MLX
METRONIDAZOLE IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES 500MG/100MLX
METRO I.V. IN PLASTIC CONTAINER
AP AM MCGAW/AM HOSP 500MG/100MLX

METRONIDAZOLE (PAGE 3-122)

TABLET; ORAL
METRONIDAZOLE
AB PAR PHARMACEUTICAL 250MGX
AB 500MGX

NANDROLONE DECANOATE (PAGE 3-125)

INJECTABLE; INJECTION
NANDROLONE DECANOATE
AO CARTER-GLOGAU 200MG/MLX
AO LEMMON 100MG/ML
50MG/ML
AO LYPHO-MED 100MG/MLX
AO MAURRY BIOLOGICAL 200MG/MLX
100MG/MLX

NAPHAZOLINE HYDROCHLORIDE (PAGE 3-125)

SOLUTION/DROPS; OPHTHALMIC
VASOCON
> DLT > AT /SMAP/PN/COOPERVISION/ /0.1%/
> ADD > AT COOPERVISION PHARMS 0.1%

NICOTINE RESIN COMPLEX (PAGE 3-127)

GUM, CHEWING; ORAL
NICORETTE
MERRELL DOW/DOW CHEM EQ 2MG BASEX

NITROGLYCERIN (PAGE 3-128)

INJECTABLE; INJECTION
NITRONAL
AP G POHL-BOSKAMP 5MG/MLX
1MG/MLX
TRIOL
AM CRITICAL CARE/AHS 0.5MG/MLX

NYSTATIN (PAGE 3-129)

OINTMENT; TOPICAL
NYSTATIN
> ADD > AT CLAY-PARK LABS 100,000 UNITS/GMX
POWDER; ORAL
NILSTAT
LEDERLE LABS/AM CYAN 100%

NYSTATIN (PAGE 3-129)	TABLET; ORAL	PAR PHARMACEUTICAL	500,000 UNITSx	/AA/ /Uttiglioni, V/ /Ed. 25mg. base/5ml/	AA	NYSTATIN	PHARMADERM/BYK-GELON	100,000 UNITSx	AT	TABLET; ORAL	PHENIMETRAZINE TARTRATE (PAGE 3-138)	TABLET; ORAL	OXPRENOLYL HYDROCHLORIDE (PAGE 3-131)	TABLET; ORAL	TRASICOR	CIBA/CIBA-GEIGY	20MGx	40MGx	160MGx	AA	ELIXIR; ORAL	OXTRIPTYLLINE (PAGE 3-131)	SYRUP; ORAL	CHOLEDYLYL	PARK-E-DAVIS/W-L	50MGx	200MGx	AA	SYRUP; ORAL	CHOLEDYLYL	POTASSIUM CHLORIDE (PAGE 3-143)	TABLET, ENTERIC COATED; ORAL	PRENDISOLONE (PAGE 3-145)	TABLET; ORAL	CHOLEDYLYL	PARK-E-DAVIS/W-L	100MGx	200MGx	AB	TABLET; ORAL	OXTRIPTYLLINE	PREDNISOLONE (PAGE 3-146)	INJECTABLE; INJECTION	PRENDISOLONE ACETATE (PAGE 3-147)	PRENDISOLONE SODIUM PHOSPHATE (PAGE 3-147)	SOLUTION/DROPS; OPHTHALMIC	/B/P/ /FERNDALE LABS/ /5mg/ml/	/B/P/ /FERNDALE LABS/ /5mg/ml/	/B/P/ /FERNDALE LABS/ /5mg/ml/	/AA/ /PARK-E-DAVIS/W-L/ /Ed. 25mg. base/	OXYTERACYCLINE HYDROCHLORIDE (PAGE 3-132)	CAPSULE; ORAL	/dylpab/	/AA/ /MSD/NEPCY/ /Ed. 6.25 mg. base/	
NYSTATIN (PAGE 3-129)	TABLET; ORAL	NYSTATIN	PAR PHARMACEUTICAL	500,000 UNITSx	/AA/ /Uttiglioni, V/ /Ed. 25mg. base/5ml/	AA	NYSTATIN	E FOUNGERA BYK-GELON	100,000 UNITSx	AT	TABLET; VAGINAL	PHENIMETRAZINE TARTRATE (PAGE 3-138)	TABLET; ORAL	OXPRENOLYL HYDROCHLORIDE (PAGE 3-131)	TABLET; ORAL	TRASICOR	CIBA/CIBA-GEIGY	20MGx	40MGx	160MGx	AA	ELIXIR; ORAL	OXTRIPTYLLINE (PAGE 3-131)	SYRUP; ORAL	CHOLEDYLYL	PARK-E-DAVIS/W-L	50MGx	200MGx	AA	SYRUP; ORAL	CHOLEDYLYL	POTASSIUM CHLORIDE (PAGE 3-143)	TABLET, ENTERIC COATED; ORAL	PRENDISOLONE (PAGE 3-145)	TABLET; ORAL	CHOLEDYLYL	PARK-E-DAVIS/W-L	100MGx	200MGx	AB	TABLET; ORAL	OXTRIPTYLLINE	PREDNISOLONE (PAGE 3-146)	INJECTABLE; INJECTION	PRENDISOLONE ACETATE (PAGE 3-147)	PRENDISOLONE SODIUM PHOSPHATE (PAGE 3-147)	SOLUTION/DROPS; OPHTHALMIC	/B/P/ /FERNDALE LABS/ /5mg/ml/	/B/P/ /FERNDALE LABS/ /5mg/ml/	/B/P/ /FERNDALE LABS/ /5mg/ml/	/AA/ /PARK-E-DAVIS/W-L/ /Ed. 25mg. base/	OXYTERACYCLINE HYDROCHLORIDE (PAGE 3-132)	CAPSULE; ORAL	/dylpab/	/AA/ /MSD/NEPCY/ /Ed. 6.25 mg. base/
NYSTATIN (PAGE 3-129)	TABLET; ORAL	NYSTATIN	PAR PHARMACEUTICAL	500,000 UNITSx	/AA/ /Uttiglioni, V/ /Ed. 25mg. base/5ml/	AA	NYSTATIN	PHARMADERM/BYK-GELON	100,000 UNITSx	AT	TABLET; VAGINAL	PHENIMETRAZINE TARTRATE (PAGE 3-138)	TABLET; ORAL	OXPRENOLYL HYDROCHLORIDE (PAGE 3-131)	TABLET; ORAL	TRASICOR	CIBA/CIBA-GEIGY	20MGx	40MGx	160MGx	AA	ELIXIR; ORAL	OXTRIPTYLLINE (PAGE 3-131)	SYRUP; ORAL	CHOLEDYLYL	PARK-E-DAVIS/W-L	50MGx	200MGx	AA	SYRUP; ORAL	CHOLEDYLYL	POTASSIUM CHLORIDE (PAGE 3-143)	TABLET, ENTERIC COATED; ORAL	PRENDISOLONE (PAGE 3-145)	TABLET; ORAL	CHOLEDYLYL	PARK-E-DAVIS/W-L	100MGx	200MGx	AB	TABLET; ORAL	OXTRIPTYLLINE	PREDNISOLONE (PAGE 3-146)	INJECTABLE; INJECTION	PRENDISOLONE ACETATE (PAGE 3-147)	PRENDISOLONE SODIUM PHOSPHATE (PAGE 3-147)	SOLUTION/DROPS; OPHTHALMIC	/B/P/ /FERNDALE LABS/ /5mg/ml/	/B/P/ /FERNDALE LABS/ /5mg/ml/	/B/P/ /FERNDALE LABS/ /5mg/ml/	/AA/ /PARK-E-DAVIS/W-L/ /Ed. 25mg. base/	OXYTERACYCLINE HYDROCHLORIDE (PAGE 3-132)	CAPSULE; ORAL	/dylpab/	/AA/ /MSD/NEPCY/ /Ed. 6.25 mg. base/
NYSTATIN (PAGE 3-129)	TABLET; ORAL	NYSTATIN	PAR PHARMACEUTICAL	500,000 UNITSx	/AA/ /Uttiglioni, V/ /Ed. 25mg. base/5ml/	AA	NYSTATIN	PHARMADERM/BYK-GELON	100,000 UNITSx	AT	TABLET; VAGINAL	PHENIMETRAZINE TARTRATE (PAGE 3-138)	TABLET; ORAL	OXPRENOLYL HYDROCHLORIDE (PAGE 3-131)	TABLET; ORAL	TRASICOR	CIBA/CIBA-GEIGY	20MGx	40MGx	160MGx	AA	ELIXIR; ORAL	OXTRIPTYLLINE (PAGE 3-131)	SYRUP; ORAL	CHOLEDYLYL	PARK-E-DAVIS/W-L	50MGx	200MGx	AA	SYRUP; ORAL	CHOLEDYLYL	POTASSIUM CHLORIDE (PAGE 3-143)	TABLET, ENTERIC COATED; ORAL	PRENDISOLONE (PAGE 3-145)	TABLET; ORAL	CHOLEDYLYL	PARK-E-DAVIS/W-L	100MGx	200MGx	AB	TABLET; ORAL	OXTRIPTYLLINE	PREDNISOLONE (PAGE 3-146)	INJECTABLE; INJECTION	PRENDISOLONE ACETATE (PAGE 3-147)	PRENDISOLONE SODIUM PHOSPHATE (PAGE 3-147)	SOLUTION/DROPS; OPHTHALMIC	/B/P/ /FERNDALE LABS/ /5mg/ml/	/B/P/ /FERNDALE LABS/ /5mg/ml/	/B/P/ /FERNDALE LABS/ /5mg/ml/	/AA/ /PARK-E-DAVIS/W-L/ /Ed. 25mg. base/	OXYTERACYCLINE HYDROCHLORIDE (PAGE 3-132)	CAPSULE; ORAL	/dylpab/	/AA/ /MSD/NEPCY/ /Ed. 6.25 mg. base/

PREDNISOLONE SODIUM PHOSPHATE (PAGE 3-147)

SOLUTION/DROPS; OPHTHALMIC

/AT/ /INFLAMASE/ /SNAP/PR/COOPERSVN/ /EQ 0.1% BASE/

INFLAMASE MILD

AT COOPERSVN PHARMS EQ 0.1% PHOSPHATE

INFLAMASE FORTE

/AT/ /SNAP/PR/COOPERSVN/ /EQ 0.8% BASE/

AT COOPERSVN PHARMS EQ 0.9% PHOSPHATE

METRETONE

AT SCHERING EQ 0.5% PHOSPHATE

> ADD >

AT PREDAIR

> ADD > AT PHARMAFAIR EQ 0.1% PHOSPHATE

PREDAIR FORTE

AT PHARMAFAIR EQ 0.9% PHOSPHATE

PREDNISOLONE SODIUM PHOSPHATE

/AT/ /BARNES-HIND PHARMS/ /0.125%/

AT BARNES-HIND PHARMS EQ 0.11% PHOSPHATE

AT EQ 0.9% PHOSPHATE

/AT/ /MAURRY BIOLOGICAL/ /EQ 0.1% BASE/

/AT/ /EQ 0.8% BASE/

AT MAURRY BIOLOGICAL EQ 0.11% PHOSPHATE

AT EQ 0.9% PHOSPHATE

PREDNISOLONE TEBUTATE (PAGE 3-147)

INJECTABLE; INJECTION

HYDELTRA-TBA

> ADD > BP MS&D/MERCK 20MG/ML

> ADD > BP PREDNISOLONE TEBUTATE

> ADD > BP CARTER-GLOGAU LABS 20MG/ML*

PREDNISONE (PAGE 3-147)

TABLET; ORAL

PREDNISONE

BX DURAMED PHARMS 5MG*

BX 10MG*

BX 20MG*

PROCAINAMIDE HYDROCHLORIDE (PAGE 3-149)

CAPSULE; ORAL

PROCAN

/AB/ PARKE-DAVIS/W-L /450MG/

/AB/ /500MG/

PROPANTHELINE BROMIDE (PAGE 3-153)

TABLET; ORAL

PROPANTHELINE BROMIDE

AA PAR PHARMACEUTICAL 15MG*

PROPOXYPHENE HYDROCHLORIDE (PAGE 3-153)

CAPSULE; ORAL

PROPOXYPHENE HCL

AA RICHLYN LABORATORIES 65MG

PROPYLTHIOURACIL (PAGE 3-154)

TABLET; ORAL

PROPYLTHIOURACIL

/BP/ /MYLAN PHARMS/ /50MG/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE (PAGE 3-155)

SYRUP; ORAL

ACTAHIST

> ADD > AA HR CENCI LABS 30MG/5ML; 1.25MG/5ML*

/PSEUDOEPHEDRINE/

/BAY LABORATORIES/ /30MG/5ML; 1.25MG/5ML/

/TRIACIN/

/NATL PHARM MF'S/BARRE/ 30MG/5ML; 1.25MG/5ML/

/TRIPOSED/

> ADD > AA HALSEY DRUG 30MG/5ML; 1.25MG/5ML*

/TRI-SUD/

/MD PHARMACEUTICAL/ /60MG; 2.5MG/

/TRIPOURINE/

/DANBURY PHARMACAL/ /60MG; 2.5MG/

/TRIPROLIDINE AND PSEUDOEPHEDRINE

AA BOLAR PHARMACEUTICAL 60MG; 2.5MG*

/WESTWARD/ /60MG; 2.5MG/

/TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL

AA CHELSEA LABORATORIES 60MG; 2.5MG*

QUINIDINE GLUCONATE (PAGE 3-157)

TABLET, CONTROLLED RELEASE; ORAL

QUINIDINE GLUCONATE

AB ROXANE LABORATORIES 324MG*

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 6 / AUGUST '83 - FEBRUARY '84
14

GUINIDINE SULFATE (PAGE 3-157)
TABLET; ORAL
GUINIDINE SULFATE 300MG
AB VITARINE/WEST CHEM
RESERPINE (PAGE 3-158)
TABLET; ORAL
GUINIDINE SULFATE 300MG
AB VITARINE/WEST CHEM
RESERPINE (PAGE 3-159)
TABLET; ORAL
SODIUM POLYSTYRENE SULFONATE
SUSPENSION; ORAL, RECTAL
AA SPS
ROXANE LABORATORIES 15GM/60ML
SODIUM POLYSTYRENE SULFONATE
INJECTABLE; INJECTION
AA CAROLINA MED PRODS 15GM/60ML
SOMATROPIN (PAGE 3-165)
INJECTABLE; INJECTION
2 IU/VIAL
SERONO LABS
ASELLACRIN 2
SPIRONOLACTONE (PAGE 3-166)
TABLET; ORAL
AB PUREPAC/KALIPHARMA 25MG
SELENIUM SULFIDE (PAGE 3-161)
LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE 2.5Z
AT BAY LABORATORIES 2.5Z
SILVER SULFADIAZINE (PAGE 3-161)
CREAM; TOPICAL
/SILVER SULFADIAZINE/
SSD
/SILVER SULFADIAZINE/
/SISSEFTATION; OINT/
/CETELIN/
/ELD. LILLY/
/35H/15H/
/STOISTEROL; ALPH/
/STOISTEROL; ALPH/ (PAGE 3-161)

SULFINPYRAZONE (PAGE 3-169)

CAPSULE; ORAL

SULFINPYRAZONE> ADD > AB VANGARD LABS/MMM 200MGXSULFISOXAZOLE (PAGE 3-170)

> DLT > /CREAM; VAGINAL/
 > DLT > /GANTRISIN/
 > DLT > /AT/ /HOFFMANN-LA ROCHE/ /10%/
 > DLT > /KORO-SULE/
 > DLT > /AT/ /HOLLAND-RANTOS/ /10%/

TERBUTALINE SULFATE (PAGE 3-173)

TABLET; ORAL

BRICANYL

> DLT > /BP/ /ASTRA PHARM PROPS/ /2.5MG/
 > DLT > /BP/ /PMS/
 > ADD > BP MERRELL DOW/DOW CHEM 2.5MG
 > ADD > BP 5MG

TESTOSTERONE (PAGE 3-173)

INJECTABLE; INJECTION

TESTOSTERONECARTER-GLOGAU LABS 50MG/MLXTETRACYCLINE HYDROCHLORIDE (PAGE 3-174)

CAPSULE; ORAL

TETRACYCLINE HCL/AB/ /LEMMON/ /250MG/

TABLET; ORAL

PANMYCIN/AB/ UPJOHN /250MG/

/AB/ SUMYCIN ER SQUIBB AND SONS 250MG

THALLOUS CHLORIDE, TL-201 (PAGE 3-175)

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201MEDI-PHYSICS 2MCI/MLTHEOPHYLLINE (PAGE 3-176)

(FOR CONTROLLED RELEASE PRODUCTS - SEE SPECIAL NOTE C.)

CAPSULE, CONTROLLED RELEASE; ORAL

SOMOPHYLLIN-CRTBC FISONS 100MGTHEO-24BC SEARLE/SEARLE PHARMS 100MGX200MGX300MGX

ELIXIR; ORAL

ELIXOMINAA HR CENCI LABS 80MG/15MLX

SOLUTION; ORAL

THEOLAIRAA RIKER LABS/3M 80MG/15MLTHEOPHYLLINEAA ROXANE LABORATORIES 80MG/15MLX

TABLET, CONTROLLED RELEASE; ORAL

THEOCONTINBC PURDUE FREDERICK 200MGX/400MG/THEO-DUR

BC KEY PHARMACEUTICALS 200MG

UNIPHYL PURDUE FREDERICK 400MG

THIORIDAZINE HYDROCHLORIDE (PAGE 3-178)

CONCENTRATE; ORAL

THIORIDAZINE HCLAA CORD LABORATORIES 30MG/MLXAA 100MG/MLXAA NATL PHARM MFG/BARRE 100MG/MLX

TABLET; ORAL

MELLARILAB SANODZ PHARMS/SANDOZ 100MGTHIORIDAZINE HCLAB BARR LABORATORIES 10MGX15MGXAB 25MGX50MGXAB 100MGX10MGXAB 100MGX100MGXAB CORD LABORATORIES 10MGX15MGXAB 25MGX50MGX

ADDENDUM
DESI PENDING LIST - 'EXEMPT' (COURT ORDER) CATEGORY
CUMULATIVE SUPPLEMENT NUMBER 6 / AUGUST '83 - FEBRUARY '84

> DLT > /ANTHOPHYLLINES; PHENOBARBITAL; RACEPHEDRINE HYDROCHLORIDE/
(PAGE AD2)

> DLT > /TABLET; ORAL/
> DLT > /AMODRINE/
> DLT > /SEARLE PHARMS/ 100MG; 30MG; 25MG/

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL;
ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE
HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A; VITAMIN E (PAGE AD2)

INJECTABLE; INJECTION

MVC PLUS

ASCOT HOSP PHARMS 10MG/ML; 0.006MG/ML; 0.5 UGM/ML;
1.5MG/ML; 20 IU/ML; 0.04MG/ML;
4MG/ML; 0.4MG/ML; 0.36MG/ML;
0.3MG/ML; 330 IU/ML; 1 IU/ML

DIPYRIDAMOLE (PAGE AD4)

TABLET; ORAL	
DIPYRIDAMOLE	
ASCOT HOSP PHARMS	50MG
DURAMED PHARMS	25MG
	50MG
	75MG
HALSEY DRUG	50MG
SUPERPHARM	50MG

ISOSORBIDE DINITRATE (PAGE AD5)

TABLET; ORAL	
ISOSORBIDE DINITRATE	
BARR LABORATORIES	30MG

> ADD >

/METHANDROSTENOLONE (PAGE AD6)

/TABLET; ORAL/	
/METHANDROSTENOLONE/	
/PAR. PHARMACEUTICAL/	2.5MG/
	5MG/

/BROMPHENTRAMINE MALEATES; PHENYLEPHRINE HYDROCHLORIDE/

/PHENYLPROPANOLAMINE HYDROCHLORIDE/ (PAGE AD3)

/ELIXIR; ORAL/
/ELIXIR, DIMEТАPP/
/AH. ROBINS/ 1.4MG/5ML; 5MG/5ML; 5MG/5ML/

/TABLET; CONTROLLED RELEASE; ORAL/
/DIMEТАPP/
/AH. ROBINS/ 12MG; 15MG; 15MG/

/CARANTHENE EDSYLATES; CHLORPHENTRAMINE MALEATES; ISOPROPANIDE/

/IODOIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE/ (PAGE AD3)

/CAPSULE; CONTROLLED RELEASE; ORAL/
/TUSS-DRNAD/

/SK&F. LABORATORIES/ 120MG; 30MG; 2.5MG; 50MG/

/SOLUTION; ORAL/
/TUSS-DRNAD/
/SK&F. LABORATORIES/ 5MG/5ML; 2MG/5ML; 0.75/5ML; 15MG/5ML/

DICYCLOMINE HYDROCHLORIDE (PAGE AD3)

SYRUP; ORAL
BAYCYCLOMINE
BAY LABORATORIES 10MG/5ML

CURRENT STATUS - INEFFECTIVE

18

DESI PENDING LIST - OTHER THAN EXEMPT. (COURT ORDER) CATEGORY
CUMULATIVE SUPPLEMENT NUMBER 6 / AUGUST 83 - FEBRUARY 84

Original from
UNIVERSITY OF MICHIGAN



UNIVERSITY OF MICHIGAN

39015 07293 3024